“…Sterling et al (2021) linked the exposure to GLP-1R agonists ( i.e., dulaglutide, liraglutide, lixisenatide, exenatide , and semaglutide ) to a low risk of developing open-angle glaucoma ( Sterling et al, 2021 ). However, previous studies have raised concern that treatment with GLP-1R agonists may increase the risk of diabetic retinopathy, making them less favorable to be used against diabetic eye complications ( Diabetes Control and Complications Trial Research Group, Nathan et al, 1993 ; No authors listed, 1998 , 1999 ; Aiello and Dcct/Edic Research Group, 2014 ; Green et al, 2015 ; Marso et al, 2016b ; Jingi et al, 2017 ; Tang et al, 2018 ; Bain et al, 2019 ; Lim et al, 2019 ; Bethel et al, 2021 ). Nevertheless, this effect of GLP-1R agonists is most likely caused by a rapid decrease in patients’ blood glucose levels as discussed later ( Vilsbøll et al, 2018 ; Bain et al, 2019 ; Lim et al, 2019 ).…”